Bill Meury, Karuna Therapeutics CEO
FDA to make decision about Karuna's schizophrenia drug by next September
The FDA is set to decide whether to approve Karuna Therapeutics’ schizophrenia drug by Sept. 26, the Boston biotech said Wednesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.